Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

39.77USD
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
$39.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,354,827
52-wk High
$44.50
52-wk Low
$36.81

Summary

Name Age Since Current Position

Serge Weinberg

65 2015 Independent Chairman of the Board

Olivier Brandicourt

60 2015 Chairman of the Executive Committee, Chief Executive Officer, Director

Jerome Contamine

58 2009 Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team

Karen Linehan

57 2014 Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team

Olivier Charmeil

53 2016 Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team

Peter Guenter

54 2016 Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team

Carsten Hellmann

52 2013 Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team

David Loew

2016 Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team

David Meeker

2013 Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team

Roberto Pucci

52 2009 Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team

Philippe Luscan

54 2015 Executive Vice President, Global Industrial Affairs, President of Sanofi in France, Member of the Executive Committee and the Senior Leadership Team

Muzammil Mansuri

62 2016 Executive Vice President, Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team

Ameet Nathwani

2016 Executive Vice President, Medical Affairs, Member of the Executive Committee and the Senior Leadership Team

George Grofik

Vice President of Investor Relations

Elias Zerhouni

65 2011 President of Global Research & Development, Member of the Executive Committee and the Senior Leadership Team

Laurent Attal

58 2012 Director

Christian Mulliez

55 2004 Director

Robert Castaigne

70 2012 Independent Director

Claudie Haignere

59 2008 Independent Director

Patrick Kron

62 2014 Independent Director

Fabienne Lecorvaisier

54 2013 Independent Director

Suet-Fern Lee

58 2011 Independent Director

Carole Piwnica

58 2010 Independent Director

Diane Souza

2016 Independent Director

Thomas Suedhof

2016 Independent Director

Biographies

Name Description

Serge Weinberg

Mr. Serge Weinberg has been Independent Chairman of the Board at Sanofi S.A. since April 2, 2015. He served as the Interim Chief Executive Officer of the Company from October 29, 2014 to April 2, 2015. He is also Chairman of the Appointments and Governance Committee and the Strategy Committee at the Company. Additionally, Mr. Weinberg has been Director of VL Holding, Manager of Alret and Maremma, and Member of the Supervisory Board of Schneider Electric and Financiere BFSA, among others. Previously, he was Director of Sanofi SA from December 16, 2009 until May 17, 2010. He became Chief of Staff of the French Budget Minister, Laurent Fabius, in 1981. After a position of Deputy General Manager for Finance at the French Television Channel FR3 (1982-1983), he became Chief Executive Officer and then Chairman of the Havas Tourisme Group, the function he held from 1983 to 1987. He was then appointed CEO of Pallas Finance for three years and joined the Pinault Group in 1990 as President of CFAO. In the Pinault Group, he was then appointed Chairman and CEO of Rexel for the period from 1991 to 1995 and chaired the Management Board of the PPR Group for 10 years. In March 2005, he founded the investment firm Weinberg Capital Partners, which manages funds dedicated to LBO and real estate. Mr. Weinberg was also Non-Executive Chairman of the Board of the Accor Group from 2006 to 2009. Mr. Weinberg obtained a degree in Law from the Institut d'Etudes Politiques de Paris and obtained a degree from the ENA - Ecole Nationale d'Administration Publique in 1976.

Olivier Brandicourt

Mr. Olivier Brandicourt has been Chairman of the Executive Committee and Director of SANOFI S.A. since May 4, 2015. He was Chairman of the Executive Committee and Chief Executive Officer of the Company from April 2, 2015. He is Member of the Strategy Committee at the Company. He has 28 years of global experience in the pharmaceutical industry. He joined the Company after serving as Chief Executive Officer of Bayer Healthcare AG since 2013. He worked at Pfizer for 13 years, where he most recently served as Member of the Executive Leadership Team and as President and General Manager of the Emerging Markets and Established Products business units. Over his career at Pfizer, he served in a series of leadership positions, including heading its Global Primary Care business unit from 2009 to 2012 and its Global Specialty Care business unit from 2008 to 2009. He also led its Cardiology business in the United States, as well as several regional operations around the world. Brandicourt started his career as a Medical Director for the Region Africa at Warner-Lambert/Parke-Davis, where he held other senior positions in medical and marketing before being appointed General Manager of Canada. He also spent eight years with the Institute of Infectious and Tropical Diseases at the Pitie-Salpetriere Hospital in Paris with a focus on malaria research in West and Central Africa and two years in the Republic of Congo as a doctor. He is also an Honorary Member of the Royal College of Physicians in London and a board member of the Children’s Aid Society in New York. He studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine (University of Paris V) and holds an Advanced Degree in Cellular and Immunological Pathophysiology from the Paris Descartes University. He also holds a Master’s Degree in Biology (University of Paris XII).

Jerome Contamine

Mr. Jerome Contamine has been Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since March 16, 2009. After four years at the Cour des Comptes as a Senior State General Auditor, he joined Elf Aquitaine in 1988, as Advisor to the Chief Financial Officer, and became Group Finance Director & Treasurer in 1991. He became General Manager of Elf Petroleum Norway in 1995, after being named Deputy Vice President of Elf Upstream Division for Europe and the U.S. In 1999, he was appointed Member of the taskforce for integration with Total, in charge of the reorganization of the merged entity, TotalFinaElf, and became, in 2000, Vice President Europe and Central Asia, Upstream Division of Total. The same year, he joined Vivendi Environnement as CFO and Deputy General Manager. In 2003, he became Senior Executive Vice President, Deputy General Manager, Chief Financial Officer of Veolia Environnement and Director of Valeo. Mr. Contamine obtained a degree from the Ecole Polytechnique in 1979 and from the Ecole Nationale de la Statistique et de l'Administration de l'Economie (ENSAE). He also earned a degree from the Ecole Nationale d'Administration in 1984.

Karen Linehan

Ms. Karen Linehan has been Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since 2014. Previously, she served as Senior Vice President - Legal Affairs and General Counsel, Global Compliance Officer Interim, Member of the Executive Committee and the Global Leadership Team of the Company from 2011 to April 1, 2012. Between March 26, 2007 and 2011, she held the functions of Senior Vice President - Legal Affairs and General Counsel, Member of the Executive Committee and Management Committee of Sanofi SA. Prior to practicing law, Ms. Linehan served on the congressional staff of the Speaker of the U.S. House of Representatives from September 1977 to August 1986. Until December 1990, she was Associate in a law firm in New York, New York. In January 1991, she joined Sanofi as Assistant General Counsel of its US subsidiary. In July 1996, Ms. Linehan moved to Paris to work on international matters within the Group and she has held a number of positions within the Legal Department, most recently as Vice President - Deputy Head of Legal Operations. Ms. Linehan obtained a Bachelor of Arts degree in Literature and a Juris Doctor degree in Law, both from the Georgetown University.

Olivier Charmeil

Mr. Olivier Charmeil has been Executive Vice President and General Manager, General Medicines & Emerging Markets and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since June 2016. Prior to that, he was Executive Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team of the Company. He joined the Company as Senior Vice President - Pharmaceutical Operations in Asia-Pacific Region on February 1, 2006, the function he held until January 1, 2008, when he became appointed Senior Vice President - Pharmaceutical Operations in Asia Pacific Region and Japan for over one year, until February 2009. From then to January 1, 2011, he served as Senior Vice President - Asia/Pacific & Japan Vaccines, Member of the Management Committee of the Company. From 1989 to 1994, he worked in the Mergers and Acquisitions department of Banque de l’Union Europeenne. He joined Sanofi Pharma in 1994 as Head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Synthelabo in 1999 and Attache to the Chairman, Jean-Francois Dehecq, in 2000, before being appointed as Vice President of Development within the Sanofi-Synthelabo International Operations Division, where he was responsible for China and support functions. In 2003, Mr. Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthelabo France, before taking the post of Senior Vice President of Business Management and Support within the Pharmaceutical Operations Division. Mr. Charmeil obtained a degree from the Hautes etudes commerciales (HEC) and from the Institut d'Etudes Politiques de Paris.

Peter Guenter

Mr. Peter Guenter has been Executive Vice President and General Manager, Diabetes & Cardiovascular and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since June 2016. Prior to that, he was Executive Vice President, General Medicines and Emerging Markets, Member of the Executive Committee and the Global Leadership Team from mid-2015 and Executive Vice President in charge of Global Commercial Operations and Member of the Executive Committee and the Global Leadership Team of the Company from July 1, 2013. He holds a Masters Degree in Physical Education at the Faculty of Medicine and Health Sciences, University of Ghent, Belgium. He started his career in Sales at SmithKline in 1986. He joined the Group in 1995 and held various positions in France, Europe and Global Marketing. In 2000, he was appointed General Manager Belgium and then Vice President for Eastern Europe, Northern Europe & Scandinavia. In 2008, he was appointed General Manager, Commercial Operations for Germany, and in 2011, he was General Manager for the Multi-Country- Organization for Germany, Switzerland and Austria.

Carsten Hellmann

Mr. Carsten Hellmann has been Executive Vice President and General Manager of Merial and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since September 1, 2013. He undertook his first degree in Business Administration in Copenhagen in 1989 before completing a Master of Science in the UK in Information Management & Technology in 1990. He began his career in 1990 at Radiometer Medical A/S as a product specialist before moving into a product manager role. He joined Novo Nordisk in 1993 and held different roles in marketing, business development, strategic alliances and business intelligence with increasing responsibilities. In 1996 he joined Synthelabo and in 1997 Pronosco A/S, a diagnostics start up specialized in osteoporosis. In 2000 he was named Chief Executive Officer at Nunc where he oversaw the P&L and entire value chain of the company, from R&D to sales. After the acquisition by Fisher Scientific, he oversaw the integration processes. He joined Chr. Hansen Holding A/S in 2006 as Executive Vice President, Global Sales, and Member of the Executive Management and Board.

David Loew

Mr. David Loew has been Executive Vice President and General Manager of Sanofi Pasteur and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since June 2016. He has a degree in Finance and Marketing and an MBA from the University of St. Gallen. He started his career in the United States at Coopers & Lybrand and Hewlett Packard in 1990, before joining Roche in 1992. Over the next 21 years, he held a variety of positions with Roche including Global Oncology Head, General Manager Switzerland, Global Chief Marketing Officer & Head of Global Product Strategy, Region Head Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President Commercial Operations Europe and became Head Global Commercial Operations Sanofi Pasteur in January 2016.

David Meeker

Dr. David P. Meeker, M.D., has been Executive Vice President and General Manager of Sanofi Genzyme and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since September 1, 2013. He has been Chief Executive Officer of Genzyme since 2010 and served as Chief Executive Officer of Genzyme and Member of the Global Leadership Team of the Company from November 1, 2011 to September 1, 2013. He joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. In 1998, he was appointed Senior Vice President, Medical Affairs, before taking up the role of Senior Vice President for Therapeutics Europe. In 2003, he was appointed President of LSD Therapeutics, where he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. He was promoted to Executive Vice President of therapeutics, biosurgery and corporate operations in 2008. Prior to joining Genzyme, he was Director of the pulmonary critical care fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He received his M.D. (a Doctorate of Medicine) degree from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

Roberto Pucci

Mr. Roberto Pucci has been Executive Vice President, Human Resources and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since October 2009. He has a law degree from the University of Lausanne, Switzerland. He started his career in 1985 at Coopers & Lybrand in Geneva, Switzerland as an external auditor. He then joined Hewlett-Packard (HP) in 1987, where he held various positions in Human Resources in Switzerland and Italy including HR Manager for the European Headquarters and Human Resources Director in Italy. In 1999, he became Director, Compensation & Benefits for Agilent Technologies, a spin off from HP, and was appointed Vice President Human Resources Europe in 2003. In 2005 he moved to the United States to join Case New Holland, a subsidiary of the Fiat Group, as Senior Vice President, Human Resources, and was appointed, in 2007, Executive Vice President, Human Resources for the Fiat Group in Torino, Italy.

Philippe Luscan

Mr. Philippe Luscan has been Executive Vice President, Global Industrial Affairs, President of Sanofi in France and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since January 1, 2015. Prior to that, he was Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team and Vice President - Chemistry at the Company. He graduated from Ecole Polytechnique and from Ecole des Mines de Paris in Biotechnology. He started his career with Danone in 1987 as Head of Production. In 1990, he joined the Company as Head of site at Sanofi Chemistry in Sisteron and was then named Head of industrial affairs at Sanofi in the United States followed by an appointment as Vice President Supply Chain, before being named Vice President Chemistry in September 2006.

Muzammil Mansuri

Dr. Muzammil Mansuri, Ph.D., has been Executive Vice President, Strategy & Business Development and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since February 2016. He holds a Bachelor of Science degree in Chemistry and a Ph.D. in Organic Chemistry from the University College London. He held post-doctoral positions at the University of California, Los Angeles (UCLA) and Columbia University. He has more than 35 years of experience beginning in 1981 with Shell Research Limited where he began as a research scientist. After Shell, he spent several years with Bristol-Myers Company in various R&D roles with increasing responsibility. From 2007 to 2010, He was Chairman and Chief Executive Officer at CGI Pharmaceuticals. He most recently was Senior Vice President, Research & Development Strategy and Corporate Development at Gilead Sciences.

Ameet Nathwani

Dr. Ameet Nathwani, M.D., has been Executive Vice President, Medical Affairs and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since May 2016. He qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration. He has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and United States. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.

George Grofik

Elias Zerhouni

Dr. Elias Zerhouni, M.D., has been President of Global Research & Development and Member of the Executive Committee and the Senior Leadership Team at SANOFI S.A. since January 1, 2011. He completed his initial medical training in Algeria and continued his academic career at the Johns Hopkins University and Hospital (United States) in 1975 where he rose to the rank of professor of Radiology and Biomedical engineering. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health of the United States of America from 2002 to 2008. He was received as member of the U.S. National Academy of Sciences’ Institute of Medicine in 2000. He was appointed as Chair of Innovation at the College de France, elected member of the French Academy of Medicine in 2010 and received the Transatlantic Innovation Leadership award in December 2011. He is the author of over 200 scientific publications and has invented 8 patents. In February 2009, Sanofi him Scientific Advisor to the Chief Executive Officer and to the Senior Vice-President Research & Development. He was appointed President Global Research & Development and has served on the Executive Committee of Sanofi since January 2011. He was appointed as member of the U.S. National Academy of Engineering in 2013.

Laurent Attal

Mr. Laurent Attal has been Director of Sanofi S.A. since May 4, 2012. He is also Member of the Strategy Committee of the Company. Additionally, he has been Vice President General Manager Research and Innovation at L’Oreal since 2010. He serves as Director of Fondation d'Entreprise L'Oreal. Mr. Attal joined L'Oreal in 1986 in France as Sales Representative. Over the next several years, he held various positions within the Active Cosmetics division and was appointed CEO of Vichy in 1994. Four years later, Mr. Attal was named President of the Active Cosmetics division, with brands including Vichy, La Roche-Posay and Inneov, L'Oreal / Nestle joint venture of Nutricosmetics. In 2002, Mr. Attal became Member of the Executive Committee of L'Oreal and also oversaw the activities of the pharmaceutical company Galderma, the joint-venture between Nestle and L'Oreal. In 2005, he was appointed President and CEO of L'Oreal USA. He obtained a Doctorate of Medicine in Dermatology from the Faculty of Medicine in Paris (Faculte de Medecine de Paris), and holds a Masters of Business Administration degree from the INSEAD.

Christian Mulliez

Mr. Christian Mulliez has been Director of Sanofi S.A. since June 2004. He is also Member of the Audit and Remuneration Committees of the Company. He holds a degree from ESSEC (Ecole Superieure des Sciences Economiques et Commerciales). From 1984 to 2002, Mr. Mulliez held various positions at Synthelabo and then at Sanofi-Synthelabo, including Vice President Finance. Since 2003, he has been Executive Vice President Administration and Finance at L’Oreal. Mr. Mulliez is also Chairman of the Board of Directors of Regefi and Director of DG 17 Invest in France. He is a Director of L’Oreal USA Inc., of Galderma Pharma (Switzerland) and of The Body Shop International (United Kingdom).

Robert Castaigne

Mr. Robert Castaigne has been Independent Director of Sanofi S.A. since May 4, 2012. Prior to that, he served as Director at the Company from February 21, 2000. He is also Chairman of the Audit Committee of the Company. Additionally, Mr. Castaigne has served as Director of Vinci and Societe Generale. He has also acted as Member of the Audit, Internal Control and Risks Committee of Societe Generale, as well as Member of the Audit and Remuneration Committees of Vinci. Previously, he served as Director of Sanofi SA from February 21, 2000 to May 4, 2012. Until 2011, he held the posts of Director and Member of the Audit Committee of Compagnie Nationale a Portefeuille, among others. Between 1972 and 2008, he held various positions at the Total group, including Chief Financial Officer and Member of the Executive Committee (June 1994 to May 2008). He was also Chairman and Chief Executive Officer of Total Chimie (1996-2008) and of Total Nucleaire (1992-2008), amongst other positions. Mr. Castaigne holds a degree from the Ecole Centrale de Lille and the Ecole Nationale Superieure du Petrole et des Moteurs, and also holds a Doctorate in Economics from the Universite Paris I Pantheon Sorbonne.

Claudie Haignere

Ms. Claudie Haignere has been Independent Director of Sanofi S.A. since May 14, 2008. She is also Member of the Company's Nominating, Governance and Remuneration Committees. She began her career as a rheumatologist at Cochin Hospital in Paris in 1984. In 1996, she participated in the scientific space mission to the MIR space station (Cassiopee, Franco-Russian mission), then in 2001, in the scientific and technical space mission to the International Space Station (Andromede mission). From 2002 to 2004, she was Deputy Minister for Research and New Technologies in the French government, then Deputy Minister for European Affairs from 2004 to 2005. Between 2005 and 2009, she was Counselor to the European Space Agency (ESA). Ms. Haignere is currently a Director for several companies and foundations in France including: France Telecom, Fondation de France, Fondation CGenial, Fondation d’Entreprise L’Oreal, Fondation Lacoste, Ecole Normale Superieure, of the Campus Condorcet and the Pole de Recherche et d’Enseignement Superieur Hautes-Etudes-Sorbonne-Arts-et-Metiers. She is also Chairman of the Board of Directors of La Geode, Chairman of Universcience (Cite des Sciences et de l’Industrie and Palais de la Decouverte) as well as Member of Academie des Technologies, of Academie des Sports, of Academie Nationale de l’Air et de l’Espace.

Patrick Kron

Mr. Patrick Kron has been Independent Board Member of Sanofi S.A. since May 2014. He is Chairman of the Compensation Committee and Member of the Appointments and Governance Committee and the Strategy Committee at the Company. He is a graduate of Ecole polytechnique and the Paris Ecole des mines. He started his career in the French Ministry of Industry where he served from 1979 until 1984. He then joined the Pechiney Group where from 1984 until 1988 he held operational responsibilities in one of the Group’s most important factories in Greece, becoming manager of the Greek subsidiary. From 1988 to 1993, he occupied several senior operational and financial positions within Pechiney, first managing a group of activities in the processing of aluminium and eventually as President of the Electrometallurgy Division. In 1993, he became a member of the Executive Committee of the Pechiney Group and was appointed Chairman of the Board of the Carbone Lorraine Company, a position he held until 1997. From 1995 to 1997, he ran the Food and Health Care Packaging Sector of Pechiney and held the position of Chief Operating Officer of the American National Can Company in Chicago (USA). From 1998 to 2002, Mr. Kron was Chief Executive Officer of Imerys before joining Alstom in 2002. He has been Chief Executive Officer of Alstom since January 1, 2003, and Chairman and Chief Executive Officer since March 11, 2003. Mr. Kron was awarded the Legion d’honneur in 2004 and is Officer of National Order of Merit since 2007.

Fabienne Lecorvaisier

Ms. Fabienne Lecorvaisier has been Independent Director at SANOFI S.A. since May 2013. She is Member of the Audit Committee at the Company. She is a graduate of Ecole Nationale des Ponts et Chaussees. She began her career at Societe Generale and later held various positions at Barclays Bank and the Banque du Louvre. In 1993, she joined the Essilor Group as Development Director before being appointed Finance and Information Systems Director of Essilor America in 1996, then Chief Financial Officer of the Group in 2001 and Senior Vice-President Strategy and Acquisitions in 2007. In 2008, she was appointed Vice-President, Finance and Administration of the Air Liquide Group, and member of its Group Executive Committee. Ms. Lecorvaisier is Chief Executive Officer of Air Liquide Finance and a Director of Air Liquide France Industries as well as a Director of Air Liquide USA and a Director of Air Liquide Japan.

Suet-Fern Lee

Ms. Suet-Fern Lee has been Independent Director of Sanofi S.A. since May 6, 2011. She holds a law degree from Cambridge University. She qualified as a Barrister-at-Law at Gray’s Inn, London in 1981 before being admitted to the Singapore Bar in 1992. She is a founder of Stamford Law Corporation (Singapore), where she has been a Senior Partner since 2000. Since 2006, she is a member of the Board of Trustees of Nanyang Technological University and of the Accounting Advisory Board of National University of Singapore Business School. In 2007, she became a member of the Advisory Committee of the Singapore Management University School of Law. Ms. Lee is currently a Board Member of Axa in France and of Macquarie International Infrastructure Fund Ltd (Bermuda). In Singapore, she is a Director of the National Heritage Board, Rickmers Trust Management Pte Ltd and Stamford Coporate Services Pte Ltd. She is also Chairman of the Board of the Asian Civilizations Museum.

Carole Piwnica

Ms. Carole Piwnica has been Independent Director at Sanofi S.A. since December 15, 2010. She is Member of the Company's Audit Committee since December 13, 2011. She holds a degree in law from Universite Libre de Bruxelles and a Masters in law from New York University. She is Member of the bar of New York and Paris, and started her career in 1985 at Proskauer Rose, New York, before joining the merger & acquisitions department of Shearman & Sterling, Paris, in 1987. She was General Counsel at Gardini et Associes from 1991 to 1994 when she joined Amylum Group where she was Chairman from 1996 to 2000. Between 1996 and 2006, she was Vice-president and Board Member of Tate & Lyle Plc. Ms. Piwnica currently is a Board Member of Eutelsat Communications in France. She is also Director of Naxos UK Ltd, a company specialized in private equity consulting in the UK, Director of Big Red, Elevance and Amyris Inc. in the U.S. and Director of Louis Delhaize in Belgium.

Diane Souza

Ms. Diane Souza has been Independent Director at SANOFI S.A. since 2016. She is Member of the Compensation Committee at the Company. She is a certified public accountant. She is the former CEO of UnitedHealthcare Specialty Benefits. With over 25 years of managed care and health benefits experience, she led healthcare operations and business and large-scale systems transformation at UnitedHealthcare and Aetna, as well as delivery of the integrated market strategy for the Affordable Care Act. She was also CFO of Aetna’s Guaranteed Products business, where she was regularly involved in complex financial transactions. She has also held senior leadership positions at Deloitte and PWC.

Thomas Suedhof

Dr. Thomas Suedhof, M.D., has been Independent Director at SANOFI S.A. since 2016. He holds a Medical Degree from the University of Goettingen Medical School (Germany) and a Medical Degree from the University of Aachen (Germany). He is the Avram Goldstein Professor in the School of Medicine of Stanford University, as well as a Professor of Molecular & Cellular Physiology, Psychiatry, and Neurology. Prior to this position, he spent 25 years at the University of Texas, Southwestern, where he acted as Chairman of the Department of Neuroscience. Most of his research at that time focused on the mechanisms of synaptic information transmission which have pharmacological consequences for the treatment of neurodegenerative and neuro-psychiatric diseases. He won the Nobel Prize in Physiology or Medicine (shared with James Rothman and Randy Shekman) in 2013, the Albert Lasker Medical Basic Research Award together with Richard Scheller, as well as the Bernhard Katz Award of the Biophysical Society (shared with Reinhard Jahn).